Detalles de la búsqueda
1.
Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study.
J Clin Rheumatol
; 2024 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38880956
2.
Opportunities and challenges of lupus care in Latin America, the Middle East, and Asia-Pacific: A call to action.
Mod Rheumatol
; 2024 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38531074
3.
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Ann Rheum Dis
; 82(9): 1130-1141, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308218
4.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Ann Rheum Dis
; 82(1): 3-18, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36357155
5.
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Ann Rheum Dis
; 82(6): 773-787, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35953263
6.
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
Rheumatology (Oxford)
; 62(5): 1804-1813, 2023 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36018230
7.
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Ann Rheum Dis
; 81(2): 206-213, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34615638
8.
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
Ann Rheum Dis
; 81(4): 496-506, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35144924
9.
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
Rheumatology (Oxford)
; 61(8): 3246-3256, 2022 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897366
10.
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
Rheumatology (Oxford)
; 60(Suppl 2): ii17-ii23, 2021 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33950225
11.
Efficacy, Safety, and Immunogenicity of Biosimilar Etanercept (Enerceptan) Versus Its Original Form in Combination With Methotrexate in Patients With Rheumatoid Arthritis: A Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.
J Clin Rheumatol
; 27(6S): S173-S179, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33337815
12.
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
J Clin Rheumatol
; 27(8): e482-e490, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32826657
13.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Ann Rheum Dis
; 79(6): 685-699, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31969328
14.
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Rheumatology (Oxford)
; 59(12): 3834-3844, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32449924
15.
Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
J Clin Rheumatol
; 26(7S Suppl 2): S180-S186, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32251060
16.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Ann Rheum Dis
; 78(11): 1454-1462, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31362993
17.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Lancet
; 390(10093): 457-468, 2017 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-28629665
18.
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Curr Rheumatol Rep
; 20(12): 84, 2018 11 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30411183
19.
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Curr Rheumatol Rep
; 20(10): 57, 2018 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30094742
20.
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Ann Rheum Dis
; 76(6): 1020-1030, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28213566